Business Wire

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
Morningstar

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could ...
Nasdaq

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...
AFP

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) ...